Sleep apnea: 52 % less apnea in 6 weeks, this treatment without mask cardboard in the USA

While classic solutions againstsleep apnea Still based on bulky and nocturnal devices, technology from the United States attracts attention: exciteosa. This wireless treatment, to be used awake, promises to strengthen the muscles of the language to limit apnea during the night. Clinic, validated, and now certified for Europe … except that, despite this recognition, it remains unavailable in France.

Exciteosa: The treatment of sleep apnea that intrigues, but is long overdue in France

We know the positive pressure ventilation, the mandibular orthotics, the connected snoring sensors. But few French have heard of exciteosa, a device yet approved by the American FDA since 2021. Its particularity? It acts during the day, by gentle electrostimulation of the tongue. The idea is simple: strengthen the muscles to avoid their relaxation during sleep.

Concretely, we slide a flexible tip under the tongue, we launch a 20 -minute session from your smartphone, and we let the impulses do the work. After six weeks of daily use, studies show a significant drop in the apnea-hypopnea index (AHI). No mask, no noise, no pipe: it is this promise of comfort that seduces patients with light apnea.

The effectiveness of exciteosa is not based on hollow marketing, but on measured results, published and validated by peers. A study by the University of California in San Diego, published In Sleep and Breathingevaluated the impact of the device on 115 patients with light obstructive apnea. After six weeks of daily use (20 minutes a day), the average apnee-hypopnea (AHI) dropped from 10.2 to 6.8 events per hour-a decrease of 33 %.

In answering patients, or 78 % of the sample, the reduction even reached 52 %. The authors also noted a marked improvement in the quality of sleep, daytime alertness and a significant reduction in snoring, perceived as much by patients as by those around them. These results are added to several studies Clinics carried out between 2020 and 2023 and validated by the FDA, which authorized marketing in 2021 in the United States.

Despite obtaining From European certification MDR in early 2025, Exciteosa remains unavailable in France to date. No local distribution channel has been set up, and neither health professionals nor French patients have access to it via the usual circuits. This absence questions, especially since the regulatory framework would theoretically allow immediate marketing. It remains to be seen whether the authorities, distributors or health professionals will take the initiative to deploy this solution in the territory, even though the need for non -invasive treatment of light apnea continue to grow.

Want to save even more? Discover Our promo codes Selected for you.